SB 525334
SB 525334는 TGF-beta receptor 1 (ALK5)의 강력한 선택적 억제제 이며, ALK2, ALK3, ALK6 에 대해서는 전혀 억제효과를 나타내지 않습니다. SB 525334는 신장의 근위관세포(renal proximal tubule cell)에서 Smad2/3 by TGF-β1의 활성을 차단하며, bleomycin으로 유도된 폐섬유증(pulmonary fibrosis)를 감소시키는 것으로 보고되었습니다.
- Preparation & Storage
Soluble in organic solvents such as DMSO. DMSO up to 100mM. ( 34.342 mg/mL ) - Download TDS
ADDITIONAL INFORMATION
|
Applications:
|
FA
|
|
Synonyms:
|
SB-525334, 6-(2-(tert-Butyl)-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl)quinoxaline
|
|
Formulation:
|
Crystalline solid
|
|
Chemical Name:
|
6-[2-tert-butyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl]quinoxaline
|
|
Molecular Formula:
|
C21H21N5 |
|
Molecular Weight:
|
343.4
|
|
CAS Number
|
356559-20-1
|
|
Purity:
|
≥98%
|
|
Storage Conditions:
|
Product should be kept at -20°C.
|
|
References:
|
Higashiyama, H., Yoshimoto, D., Kaise, T., Matsubara, S., Fujiwara, M., Kikkawa, H., … & Kinoshita, M. (2007). Inhibition of activin receptor-like kinase 5 attenuates bleomycin-induced pulmonary fibrosis. Experimental and molecular pathology, 83(1), 39-46. Grygielko, E. T., Martin, W. M., Thornton, P., Tweed, C., & Laping, N. J. (2002, September). SB-525334, a novel TGF-beta type I receptor kinase inhibitor in the puromycin aminonucleoside model of renal disease. InJOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (Vol. 13, pp. 5A-5A). 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA: LIPPINCOTT WILLIAMS & WILKINS. Underwood, D. C., Osborn, R. R., Grygielko, E. T., & Laping, N. J. (2003). SB-525334, a novel TGF-beta type 1 receptor kinase inhibitor, prevents ans reverses Bleopmycin-induced pulmonary fibrosis in the rat. |
상품평
아직 상품평이 없습니다.